In conscious rats, the intrathecal (i.t.) injection of
endothelin-1 (ET-1; 65-650 pmol) and
endothelin-3 (ET-3; 162-650 pmol) produced dose-dependent increases of mean arterial blood pressure (MAP) accompanied by either a
tachycardia or a
bradycardia. A number of animals died by a sudden respiratory arrest. ET-3 was less toxic and less potent than ET-1 on MAP and heart rate (HR) while
BQ-3020, a selective ETB agonist, had no toxic effect and exhibited only a weak pressor effect on blood pressure. The prior i.t. injection of 65 nmol
BQ-123, a selective ETA receptor antagonist, blocked both the cardiovascular and toxic effects of ET-1 but failed to modify the cardiovascular effect evoked by i.t.
substance P (6.5 nmol) or to cause intrinsic cardiovascular and toxic effects. While the pressor response to ET-1 was significantly inhibited after i.v. injection of
phentolamine, the
bradycardia was blocked by
pentolinium. The cardiovascular response to ET-1 was, however, unaffected in rats either sympathectomized with
6-hydroxydopamine or pretreated with
capsaicin. Furthermore, big ET-1 (100 pmol) caused toxic effects and delayed cardiovascular changes which were prevented by the prior i.t. administration of either
BQ-123 (65 nmol) or 100 nmol
phosphoramidon, an
endothelin-converting enzyme (ECE) inhibitor. These results suggest: (1) that the cardiovascular and toxic effects of i.t.
endothelins are mediated by ETA receptors in the rat spinal cord; (2) that the pressor response and
bradycardia are likely due to the activation of the sympatho-adrenal nervous system and to a vagal reflex mechanism, respectively; and (3) that a
phosphoramidon-sensitive ECE converts big ET-1 to ET-1 in the rat spinal cord.